Volume 31, Number 8—August 2025
CME ACTIVITY - Research
Scheffersomyces spartinae Fungemia among Pediatric Patients, Pakistan, 2020–2024
Table 3
Subclade characteristics from Scheffersomyces spartinae fungemia among pediatric patients, Pakistan, 2020–2024*
Characteristics |
Clade, no. (%) |
p value |
|
---|---|---|---|
A-1, n = 52 |
A-2, n = 47 |
||
Age group | |||
<2 wk | 12 (23.1) | 23 (48.9) | 0.011 |
2–3 wk | 10 (19.2) | 21 (44.7) | 0.0090 |
1–6 mo | 5 (9.6) | 0 | 0.058 |
7–11 mo | 6 (11.5) | 1 (2.1) | 0.11 |
1–6 y | 13 (25) | 1 (2.1) | 0.001 |
7–12 y |
6 (11.5) |
1 (2.1) |
0.11 |
Hospital | |||
A | 0 | 1 (2.1) | 0.47 |
B | 5 (9.6) | 0 | 0.058 |
C | 0 | 1 (2.1) | 0.47 |
D | 1 (1.9) | 0 | 1 |
E | 0 | 1 (2.1) | 0.47 |
F | 1 (1.9) | 0 | 1 |
G | 1 (1.9) | 0 | 1 |
H | 36 (69.2) | 37 (78.7) | 0.36 |
I | 1 (1.9) | 0 | 1 |
J | 0 | 1 (2.1) | 0.47 |
K | 0 | 1 (2.1) | 0.47 |
Unknown | 7 (13.5) | 5 (10.6) | 0.76 |
*All p values from Fisher exact test comparing values for each age group or hospital to values from all other age groups or hospitals. Bold font indicates statistical significance.
Page created: June 02, 2025
Page updated: July 24, 2025
Page reviewed: July 24, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.